Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism.

Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R.

Lung Cancer. 2014 Feb;83(2):189-96. doi: 10.1016/j.lungcan.2013.11.001. Epub 2013 Nov 13.

2.

FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.

Kohutek ZA, Wu AJ, Zhang Z, Foster A, Din SU, Yorke ED, Downey R, Rosenzweig KE, Weber WA, Rimner A.

Lung Cancer. 2015 Aug;89(2):115-20. doi: 10.1016/j.lungcan.2015.05.019. Epub 2015 May 28.

3.

Prognostic value of FDG uptake in early stage non-small cell lung cancer.

Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, Poncelet AJ.

Eur J Cardiothorac Surg. 2008 May;33(5):819-23. doi: 10.1016/j.ejcts.2008.02.005.

PMID:
18374589
4.

Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S, Cortese N, Qehajaj D, Pistillo D, Alloisio M, Roncalli M, Allavena P, Santoro A, Marchesi F, Chiti A.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.

PMID:
27251642
5.

FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.

Nguyen XC, Lee WW, Chung JH, Park SY, Sung SW, Kim YK, So Y, Lee DS, Chung JK, Lee MC, Kim SE.

Eur J Radiol. 2007 May;62(2):214-9. Epub 2007 Jan 18.

PMID:
17239556
6.

Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.

Everitt SJ, Ball DL, Hicks RJ, Callahan J, Plumridge N, Collins M, Herschtal A, Binns D, Kron T, Schneider M, MacManus M.

J Nucl Med. 2014 Jul;55(7):1069-74. doi: 10.2967/jnumed.113.131631. Epub 2014 May 15.

7.

PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer.

Nair VS, Barnett PG, Ananth L, Gould MK; Veterans Affairs Solitary Nodule Accuracy Project Cooperative Studies Group.

Chest. 2010 May;137(5):1150-6. doi: 10.1378/chest.09-2356. Epub 2009 Dec 28.

PMID:
20038738
8.

Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer.

Duan XY, Wang W, Wang JS, Shang J, Gao JG, Guo YM.

BMC Cancer. 2013 Nov 15;13:546. doi: 10.1186/1471-2407-13-546.

9.

Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.

Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.

Ann Surg. 2013 Feb;257(2):364-70. doi: 10.1097/SLA.0b013e318262a6ec.

PMID:
22968069
10.

Relationship between 18F-FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas.

Zhou X, Chen R, Xie W, Ni Y, Liu J, Huang G.

J Nucl Med. 2014 Nov;55(11):1766-71. doi: 10.2967/jnumed.114.145490. Epub 2014 Oct 23.

11.

Prognostic value of 18-FDG uptake in early stage NSCLC.

Chen JC, Huang TW, Cheng YL, Chang H, Tzao C, Huang WS, Lee SC.

Thorac Cardiovasc Surg. 2009 Oct;57(7):413-6. doi: 10.1055/s-0029-1185733. Epub 2009 Sep 30.

PMID:
19795329
12.

[Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].

Zhao SJ, Wu N, Zheng R, Liu Y, Zhang WJ, Liang Y, Zhang H, Li XM.

Zhonghua Zhong Liu Za Zhi. 2013 Oct;35(10):754-7. Chinese.

PMID:
24378097
13.

Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.

Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.

Biomed Mater Eng. 2014;24(6):3091-103. doi: 10.3233/BME-141131.

PMID:
25227018
14.

Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.

Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T.

Eur J Radiol. 2012 Dec;81(12):4179-84. doi: 10.1016/j.ejrad.2012.07.009. Epub 2012 Aug 9.

PMID:
22884163
15.

Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.

Zhang D, Jin X, Wang F, Wang S, Deng C, Gao Z, Guo C.

Ann Surg Oncol. 2007 Dec;14(12):3581-92. Epub 2007 Sep 27.

PMID:
17899287
16.

Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.

Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, Vera P.

J Nucl Med. 2015 Feb;56(2):196-203. doi: 10.2967/jnumed.114.144253. Epub 2015 Jan 8.

17.

Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.

Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, Gao F, Dehdashti F, Patterson A, Siegel BA, Govindan R.

J Thorac Oncol. 2008 Feb;3(2):130-4. doi: 10.1097/JTO.0b013e318160c122.

18.

Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.

Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8. doi: 10.1007/s00259-013-2530-8. Epub 2013 Aug 16.

PMID:
23948859
19.

Prognostic evaluations of small size lung cancers by 18F-FDG PET/CT and thin-section CT.

Kishimoto M, Iwano S, Ito S, Kato K, Ito R, Naganawa S.

Lung Cancer. 2014 Nov;86(2):180-4. doi: 10.1016/j.lungcan.2014.09.006. Epub 2014 Sep 16.

PMID:
25263854
20.

FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.

Kwon W, Howard BA, Herndon JE, Patz EF Jr.

J Thorac Oncol. 2015 Jun;10(6):897-902. doi: 10.1097/JTO.0000000000000534.

Supplemental Content

Support Center